Gerrina Ruiter, MD, PhD, on Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Baseline Brain Metastases

September 22, 2025 By The ASCO Post Staff

Gerrina Ruiter, MD, PhD, of the Netherlands Cancer Institute, discusses data from the Beamion LUNG-1 trial, which is evaluating zongertinib—an irreversible tyrosine kinase inhibitor that selectively inhibits HER2 while sparing EGFR—in patients with HER2-mutant advanced or metastatic non–small cell lung cancer (NSCLC). This analysis of the trial focused on previously treated patients with active brain metastases (cohort 4) or stable/asymptomatic brain metastases (cohort 1) at baseline (Abstract PT2.12.03).

Related Content